KKR Injects $60M In Slayback Pharma
As part of the deal, KKR’s Ali Satvat and Neel Varshney will join Slayback’s board of directors, according to a statement announcing the commitment. Slayback CEO Ajay Singh said the relationship will benefit the company beyond the capital injection.
“In addition to being a highly regarded long-term capital partner,...
To view the full article, register now.